Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
0.2253
+0.0115 (5.38%)
At close: Nov 20, 2026, 4:00 PM EST
0.2004
-0.0249 (-11.05%)
After-hours: Nov 20, 2026, 7:56 PM EST
Actuate Therapeutics Employees
Actuate Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 2 or 20.00% compared to the previous year. That makes Actuate Therapeutics the 39,630th largest employer in the world and 5,862nd in the United States.
Employees
12
Change (1Y)
2
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,538,916
Market Cap
12.39M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 2 | 20.00% |
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Sep 30, 2024 | 11 | 6 | 120.00% |
| Jun 30, 2024 | 11 | - | - |
| Mar 31, 2024 | 10 | - | - |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| Passage Bio | 24 |
| Jasper Therapeutics | 22 |
| BioCardia | 21 |
| Quantum BioPharma | 17 |
| Tvardi Therapeutics | 12 |
| Psyence Biomedical | 12 |
| Purple Biotech | 10 |
ACTU News
- 3 days ago - Actuate reports up to 77% melanoma tumor growth inhibition with oral elraglusib - TheFly
- 4 days ago - Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026 - GlobeNewsWire
- 6 days ago - Actuate Therapeutics price target lowered to $10 from $15 at H.C. Wainwright - TheFly
- 9 days ago - Actuate Therapeutics Quarterly report: Q3 2026 - Filings
- 9 days ago - Actuate Therapeutics Slides: Corporate presentation - Filings
- 18 days ago - Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026 - GlobeNewsWire
- 19 days ago - Actuate Therapeutics receives notice of allowance for Elraglusib patent - TheFly
- 20 days ago - Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets - GlobeNewsWire